Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Next Previous
X
Search
Trial Profile

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Anal cancer; Carcinoma; Colorectal cancer; Ductal carcinoma; Gastrointestinal cancer; Pancreatic cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOBLET

    • Most Recent Events

    • 18 Dec 2024 According to an Oncolytics Biotech media release, the company announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025.
    • 03 Dec 2024 According to an Oncolytics Biotech media release, the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study following their review of initial safety data. Enrollment in this cohort will resume pending final approval from the Paul Ehrlich Institute (PEI), Germany's medical regulatory body. Additional updates are expected in 2025, with safety data anticipated in the first half and initial efficacy results in the second half.
    • 03 Dec 2024 According to an Oncolytics Biotech media release, early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab. This study will begin with 30 patients, with an option to expand to an additional 34 participants

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top